EGFR and neoplasm: Similarly, ctDNA in plasma provides an alternative to tumor samples for EGFR mutation analysis, and plasma gene mutations showed greater advantages than solid tumor cells for revealing the genetic landscape of primary and metastatic lesions, which are relatively limited.